- Home
- LSEAW vs OCEAW Comparison
LSEAW vs OCEAW Comparison
Compare LSEAW & OCEAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSEAW
- OCEAW
- Stock Information
- Founded
- LSEAW 2013
- OCEAW N/A
- Country
- LSEAW United States
- OCEAW United States
- Employees
- LSEAW N/A
- OCEAW 7
- Industry
- LSEAW Homebuilding
- OCEAW Biotechnology: Pharmaceutical Preparations
- Sector
- LSEAW Consumer Discretionary
- OCEAW Health Care
- Exchange
- LSEAW Nasdaq
- OCEAW Nasdaq
- Market Cap
- LSEAW N/A
- OCEAW N/A
- IPO Year
- LSEAW N/A
- OCEAW 2021
- Fundamental
- Price
- LSEAW $0.07
- OCEAW $0.03
- Analyst Decision
- LSEAW
- OCEAW
- Analyst Count
- LSEAW 0
- OCEAW 0
- Target Price
- LSEAW N/A
- OCEAW N/A
- AVG Volume (30 Days)
- LSEAW 12.4K
- OCEAW N/A
- Earning Date
- LSEAW 02-27-2025
- OCEAW N/A
- Dividend Yield
- LSEAW N/A
- OCEAW N/A
- EPS Growth
- LSEAW N/A
- OCEAW N/A
- EPS
- LSEAW 0.73
- OCEAW N/A
- Revenue
- LSEAW $1,461,271,000.00
- OCEAW N/A
- Revenue This Year
- LSEAW N/A
- OCEAW N/A
- Revenue Next Year
- LSEAW N/A
- OCEAW N/A
- P/E Ratio
- LSEAW $11.12
- OCEAW N/A
- Revenue Growth
- LSEAW 18.01
- OCEAW N/A
- 52 Week Low
- LSEAW $0.11
- OCEAW N/A
- 52 Week High
- LSEAW $0.12
- OCEAW N/A
- Technical
- Relative Strength Index (RSI)
- LSEAW N/A
- OCEAW N/A
- Support Level
- LSEAW N/A
- OCEAW N/A
- Resistance Level
- LSEAW N/A
- OCEAW N/A
- Average True Range (ATR)
- LSEAW 0.00
- OCEAW 0.00
- MACD
- LSEAW 0.00
- OCEAW 0.00
- Stochastic Oscillator
- LSEAW 0.00
- OCEAW 0.00
Stock Price Comparison Chart: LSEAW vs OCEAW
About LSEAW Landsea Homes Corporation Warrant
Landsea Homes Corp is a homebuilding company. It designs and builds homes and sustainable master-planned communities in some of the nation's desirable markets. The company's segments include Arizona, California, Florida, Metro New York, and Texas. It derives a majority of revenue from home sales in Florida.
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.